EL-Anti-SARS-CoV-2 IgG Kit, Catalog #104-130. Submitted as EUA202128
The cross-reactivity of the device may present an increased level of potential false positives. Submitted as EUA202128
US Nationwide distribution in the states of California, Florida, Illinois, Indiana, North Carolina, and Texas.
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=Z-2382-2021